Page last updated: 2024-11-13

mulundocandin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

mulundocandin: a cyclic hexapeptide echinocandin from Aspergillus sydowi No. Y-30462; active against yeasts and filamentous fungi; MF: C48-H77-N7-O16; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID121225706
MeSH IDM0148027

Synonyms (8)

Synonym
echinocandin b, 1-(4,5-dihydroxy-n-(12-methyl-1-oxotetradecyl)ornithine)-5-serine-
mulundocandin
108351-20-8
unii-lgz0kkq79a
lgz0kkq79a ,
echinocandin b, 1-(4,5-dihydroxy-n2-(12-methyl-1-oxotetradecyl)ornithine)-5-serine-
l-proline, (4r,5r)-4,5-dihydroxy-n2-(12-methyl-1-oxotetradecyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(4-hydroxyphenyl)-l-threonyl-l-seryl-3-hydroxy-4-methyl-, cyclic (6->1)-peptide, (2.alpha.,3.beta.,4.beta.)-
Q27282978

Research Excerpts

Overview

Mulundocandin (MCN) is an antifungal lipopeptide. It belongs to the echinocand in class of antimycotic agents.

ExcerptReferenceRelevance
"Mulundocandin (1), is an echinocandin class of lipopeptide. "( Semisynthetic modifications of hemiaminal function at ornithine unit of mulundocandin, towards chemical stability and antifungal activity.
Chatterjee, DK; Dikshit, V; Gangopadhyay, AK; Gund, VG; Lal, B; Nadkarni, SR; Shirvaikar, R, 2003
)
1.99
"Mulundocandin (MCN) is an antifungal lipopeptide which belongs to the echinocandin class of antimycotic agents. "( Mulundocandin, an echinocandin-like lipopeptide antifungal agent: biological activities in vitro.
Borgonovi, M; Hawser, S; Isert, D; Markus, A, 1999
)
3.19
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (14.29)18.7374
1990's2 (14.29)18.2507
2000's9 (64.29)29.6817
2010's1 (7.14)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (92.86%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]